April 23, 2026Journal of the American College of Cardiology835 citations
View Full Paper2021 Update to the 2017 ACC Expert Consensus Decision Pathway for Optimization of Heart Failure Treatment: Answers to 10 Pivotal Issues About Heart Failure With Reduced Ejection Fraction
Key Points
- To provide updated guidance on optimizing treatment for heart failure with reduced ejection fraction based on recent evidence.
- Reviewed 2017 ACC expert consensus and updated recommendations in light of new research findings.
- Focused on 10 key questions regarding treatment strategies for heart failure with reduced ejection fraction.
- Identified new therapeutic interventions that enhance patient outcomes.
- Clarified the role of ejection fraction in treatment decision-making for heart failure.
- Highlighted evidence-based updates to existing treatment pathways.
Abstract
No abstract was published with this document — society guidelines, consensus pathways, and scientific statements are typically released without one. See the Key Points and the linked PDF for the full content.
Expert Takes4 quotes
1/4
“Relative to an ACE inhibitor and a beta-blocker alone, optimal implementation of the current guideline-directed medical therapies can extend medical survival by more than 6 years.”
Gregg C. Fonarow, Chief of cardiology, University of California Los AngelesUniversity of California, Los Angelesauto_pipelineView source